Statin-Shy? Why I Still Reach for a Statin First, and What I Do When You Truly Can't Take One

August 9, 2026

There is a lot of statin fear out there, and I do not blame patients for feeling it. Open any browser, scroll any feed, or stand in line at the pharmacy long enough and you will hear that statins wreck your muscles, fog your brain, and wreck your liver. By the time some patients reach my Encinitas office, they have already decided the answer is no, often before we have looked at a single number.

I want to take that fear seriously, because brushing it off is both disrespectful and bad medicine. Some statin worry is overblown. Some of it is very real. The best part of practicing cardiology right now is that even when a statin truly does not work for a patient, I am no longer stuck telling them to either suffer through side effects or leave dangerous cholesterol untreated. Those are no longer the only two doors.

Some of the fear is the nocebo effect, and some of it is real

You have heard of the placebo effect, where a sugar pill makes people feel better because they expect it to. Flip that around and you get the nocebo effect. When you expect a pill to hurt you, your body can produce real symptoms from that expectation alone. That pain is not imaginary. Worry and anticipation alone can make the brain generate genuine aches.

Statins are a textbook case. Roughly one in four patients who start a statin reports muscle aching. That sounds damning until you look at the blinded studies. Researchers took people who had quit statins because of muscle pain and cycled them through months on the real statin, months on an identical-looking placebo, and months on nothing, without telling them which was which. The pain scores on the statin and on the placebo came out nearly the same, and both were higher than the no-pill stretch.

The pain was real.

It just wasn’t the pill causing it, for most of these people. Bracing for pain while swallowing a tablet was enough to bring the pain on.

Here is where I part ways with the dismissive version of this story. A real minority of people truly cannot tolerate statins. True statin muscle pain has a recognizable pattern. It starts within weeks of beginning the drug or raising the dose, it hits the big muscles of the shoulders, hips, and thighs on both sides, and it eases when the drug stops and returns when it restarts. I had a patient last year who fit that pattern exactly. Both shoulders started aching within two weeks of his first dose, the pain eased within days of stopping, and it came right back when he restarted at my suggestion to confirm the pattern before we gave up on the drug class. We ended up switching him to a different statin at a lower dose, and the ache never returned. Myalgia, the medical word for muscle aching, is the most common real side effect of this class. When a patient has that pattern, I take it seriously and we change course. Telling that person it is all in their head would be wrong and a little cruel.

So both things are true at once. Much of the fear is driven by expectation and by the general aches that come with getting older. And a real slice of patients truly do have a problem with these drugs. My job is to sort out which group you are in, not to wave the question away.

We finally have excellent backups

For most of my career, statin intolerance was a real bind. Cholesterol still needed to come down, the statin was the only strong tool, and a patient who could not take it was left exposed. That era is over. We now have a deep bench of non-statin options, and they are good.

Ezetimibe is an inexpensive daily pill that blocks cholesterol absorption in the gut. On its own it lowers cholesterol modestly. Paired with even a tiny dose of a statin, or stacked with the options below, it pulls real weight.

Bempedoic acid, sold as Nexletol, is a newer pill that shuts down cholesterol production through a different route than statins. What’s clever is where it does its work. It activates mainly in the liver and barely touches muscle tissue, so the muscle aching that drives people away from statins tends not to show up. In a large trial of more than 13,000 statin-intolerant patients, it lowered the rate of major cardiovascular events. For someone who truly cannot take a statin, this is usually my first move ahead of an injectable, since most patients would rather swallow a pill than give themselves a shot.

PCSK9 inhibitors are injectable medicines that lower LDL cholesterol dramatically by helping the liver clear cholesterol from the blood. Two of them, evolocumab (Repatha) and alirocumab (Praluent), are given as a shot every two weeks and have been proven to cut heart attacks and strokes. A third option, inclisiran (Leqvio), works through a related mechanism and is given as an injection just twice a year after the initial doses. These are outstanding tools for patients who cannot tolerate statins or who need to push their numbers far lower than a statin alone can manage.

Add it up and the message is simple. If you and I discover that you truly cannot take a statin, we are not out of options. We have a path that protects you without leaving you in pain.

So why do I still reach for a statin first?

If the alternatives are this good, you might fairly ask why I still start most patients on a statin. Part of the answer is the obvious stuff. Statins are cheap, they come as a once-a-day pill, and we have decades of safety data behind them. Most people tolerate them with no trouble at all.

Patients rarely hear about the rest of it. Statins come with a long list of bonus benefits that reach well past the cholesterol number, and that list is a big reason I still love them as a starting point.

They steady the plaque itself. This is my favorite. Imaging studies show that strong statin therapy changes the makeup of the fatty plaques in your arteries. The soft, inflamed, rupture-prone core shrinks, the protective cap over the plaque thickens, and the calcium inside it shifts to a denser, more stable form. A stable plaque is far less likely to crack open and trigger a heart attack. Statins also lower a blood marker of inflammation called CRP, something most other cholesterol drugs do not do on their own. That’s a different kind of protection than a lower number on a lab report, and it’s the clearest sign a statin is doing real work in the artery wall.

They prevent strokes. Statins lower the risk of a first stroke by about a fifth and cut the odds of a second stroke in people who have already had one. The protection is strongest against the common clot-type stroke.

They save legs. In a Veterans Affairs analysis of more than 150,000 people with poor circulation in the legs from clogged arteries, high-intensity statins lowered the risk of amputation by about a third and the risk of death by about a quarter. For those patients, a statin is not optional in my book.

They protect the kidneys. In people with chronic kidney disease who are not yet on dialysis, statins lower the chance of heart attack, stroke, and death, with strong evidence behind it.

They may protect the brain. This one is promising rather than proven, so I hold it loosely. When researchers pooled dozens of cohort studies, statin users had roughly a fifth lower rate of dementia and nearly a third lower rate of Alzheimer’s disease, and a separate study found the protective signal was strongest in people carrying the strongest genetic risk for Alzheimer’s. This is observational evidence, not a blinded trial, so it can’t prove cause and effect, and larger randomized trials in older adults are still underway. What I can say with confidence is that statins do not appear to harm memory, despite the rumor that they do.

They lower the odds of dangerous blood clots. Statins seem to make blood a little less prone to forming the clots that start in the legs and travel to the lungs. A 2024 Cochrane review of 27 trials in more than 122,000 patients found a modest reduction.

They help people live longer. LDL cholesterol tracks with death risk over a lifetime, and lowering it with a statin shows up in that number too. In people taking a statin to prevent a first cardiac event, the risk of dying from any cause drops by around 14 percent.

No other lipid medicine carries this full package. Alternatives lower cholesterol, and that matters, but the statin brings extras the others have not been shown to match. When a patient can tolerate one, I want them to have all of it.

How I actually decide

My approach is statin-first, then adjust. If you tolerate a statin, you get the cholesterol lowering plus the bonus benefits, and we are done. If you report muscle pain, we don’t stop there. We run a careful trial off and back on, we try a lower dose or a different statin, and we use the three-times-a-week trick that works for some people. If it turns out you truly cannot take any statin, we move to ezetimibe, bempedoic acid, or a PCSK9 inhibitor and protect you that way.

One move I will always push back on is walking away from cholesterol treatment entirely. High cholesterol is silent and patient. It doesn’t hurt today, and it does its damage quietly over decades until it shows up as a heart attack or a stroke. Whatever path we take, the goal stays the same. Steady, lifelong protection. There is almost always a way to get there, and it doesn’t have to cost you how you feel day to day.

Frequently Asked Questions

Is my statin muscle pain real or in my head?

The pain is real either way. Figuring out why is the real task. Blinded studies show that most reported statin muscle pain is not actually caused by the pill, but a real minority of people truly do react to it. A careful trial off the drug and then back on is the way to tell which group you are in, not a guess. This is not a judgment of you or your perception.

What are the best alternatives if I can’t take a statin?

Ezetimibe (an inexpensive daily pill), bempedoic acid (Nexletol, a pill that barely touches muscle tissue), and the injectable PCSK9 inhibitors evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio) are the main options. Several of these have been proven to lower heart attacks and strokes, so you are not trading away protection by switching.

If the alternatives are so good, why bother with a statin at all?

Statins come with bonus benefits the alternatives have not been shown to match. Steadier plaque, lower inflammation, fewer strokes, kidney and leg protection, and possibly lower dementia risk. They are also cheap, once daily, and backed by decades of safety data. For a patient who tolerates one, that full package is hard to beat.

Will a statin hurt my memory?

The better evidence points the other way. Statin users in large studies had lower rates of dementia, not higher, and statins do not appear to harm memory. If fear of brain fog has kept you from treatment, that fear is not supported by the stronger data.

Can I just stop once my cholesterol looks good?

Usually not. The number looks good because the medication is working. Keeping the protection, including the bonus benefits, means staying on it. Stopping lets the cholesterol and the risk drift back up.

References

1. Howard, James P., Frances A. Wood, Judith A. Finegold, et al. “Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment.” Journal of the American College of Cardiology 78, no. 12 (2021): 1210-1222.

2. Wood, Frances A., James P. Howard, Judith A. Finegold, et al. “N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.” New England Journal of Medicine 383, no. 22 (2020): 2182-2184.

3. Nissen, Steven E., A. Michael Lincoff, Danielle Brennan, et al. “Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.” New England Journal of Medicine 388, no. 15 (2023): 1353-1364.

4. Oesterle, A., U. Laufs, and J. K. Liao. “Pleiotropic Effects of Statins on the Cardiovascular System.” Circulation Research (2017).

5. van Rosendael, A. R., I. J. van den Hoogen, U. Gianni, et al. “Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition.” JAMA Cardiology (2021).

6. Diener, H. C., and G. J. Hankey. “Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar.” Journal of the American College of Cardiology (2020).

7. Arya, Shipra, Anjali Khakharia, Zachary O. Binney, Randall R. DeMartino, Luke P. Brewster, Philip P. Goodney, and Peter W. F. Wilson. “Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.” Circulation 137, no. 14 (2018): 1435-1446.

8. Tunnicliffe, D. J., S. C. Palmer, B. A. Cashmore, et al. “HMG CoA Reductase Inhibitors (Statins) for People With Chronic Kidney Disease Not Requiring Dialysis.” Cochrane Database of Systematic Reviews (2023).

9. Du, Ye, Zhangjie Yu, Chengyi Li, Yanxing Zhang, and Buyun Xu. “The Role of Statins in Dementia or Alzheimer’s Disease Incidence: A Systematic Review and Meta-Analysis of Cohort Studies.” Frontiers in Pharmacology (2025).

10. Rajan, Kumar B., Elizabeth A. Mcaninch, Robert S. Wilson, Ashwin Dhana, et al. “Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults.” Neurology 102 (2024): e209168.

11. Wang, Zixin, Peng Zhang, Jinhui Tian, Peizhen Zhang, Kehu Yang, and Lun Li. “Statins for the Primary Prevention of Venous Thromboembolism.” Cochrane Database of Systematic Reviews (2024).

12. Chou, R., T. Dana, I. Blazina, M. Daeges, and T. L. Jeanne. “Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2016).

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.